Ralliant Corporation $RAL Stock Position Boosted by Gabelli Funds LLC

Gabelli Funds LLC raised its stake in shares of Ralliant Corporation (NYSE:RAL) by 28.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 38,257 shares of the company’s stock after buying an additional 8,421 shares during the period. Gabelli Funds LLC’s holdings in Ralliant were worth $1,591,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in RAL. Cetera Investment Advisers acquired a new stake in shares of Ralliant in the 2nd quarter worth approximately $700,000. Russell Investments Group Ltd. bought a new position in shares of Ralliant in the second quarter valued at approximately $1,465,000. EverSource Wealth Advisors LLC acquired a new position in shares of Ralliant during the second quarter valued at approximately $39,000. First Trust Advisors LP acquired a new position in shares of Ralliant during the second quarter valued at approximately $2,013,000. Finally, Federated Hermes Inc. bought a new stake in Ralliant during the second quarter worth approximately $326,000.

Ralliant Price Performance

Shares of NYSE:RAL opened at $66.85 on Thursday. Ralliant Corporation has a one year low of $37.27 and a one year high of $75.41. The stock has a fifty day moving average of $66.98 and a 200-day moving average of $54.16. The company has a market capitalization of $7.48 billion and a PE ratio of -6.11. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.05 and a current ratio of 1.61.

Ralliant (NYSE:RAL) last released its quarterly earnings data on Tuesday, May 12th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.08. The business had revenue of $534.60 million during the quarter. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.Ralliant’s revenue was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. As a group, equities analysts anticipate that Ralliant Corporation will post 2.64 EPS for the current fiscal year.

Ralliant Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 23rd. Investors of record on Monday, June 8th were given a $0.05 dividend. The ex-dividend date was Monday, June 8th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Ralliant’s dividend payout ratio (DPR) is -1.83%.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Oppenheimer upped their target price on Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 13th. Truist Financial reiterated a “buy” rating and set a $68.00 price target (up from $53.00) on shares of Ralliant in a research report on Wednesday, May 13th. Evercore initiated coverage on Ralliant in a research note on Tuesday, June 9th. They issued an “outperform” rating and a $80.00 price objective on the stock. Wall Street Zen lowered Ralliant from a “buy” rating to a “hold” rating in a report on Sunday. Finally, TD Cowen raised their target price on Ralliant from $55.00 to $70.00 and gave the company a “buy” rating in a research note on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $73.00.

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.